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Abstract
We previously reported that BRCA1/2-mutated fallopian tube epithelium (FTE) collected during
the luteal phase exhibits gene expression proﬁles more closely resembling that of high-grade
serous carcinoma (HGSC) specimens than FTE collected during the follicular phase or from
control patients. Since the luteal phase is characterised by high levels of progesterone, we
determined whether the expression of progesterone receptor (PR) and PR-responsive genes was
altered in FTE obtained from BRCA mutation carriers during the luteal phase of the menstrual
cycle. RT-qPCR conﬁrmed a decreased expression of PR mRNA in FTE during the luteal phase
relative to follicular phase, in both BRCA1/2 mutation carriers and control patients.
Immunohistochemistry using isoform-speciﬁc antibodies conﬁrmed a low level of both PR-A
and PR-B in HGSC and a lower level of staining in FTE samples obtained during the luteal phase
compared with the follicular phase. No signiﬁcant difference in PR-A or PR-B staining was found
based on patient BRCA mutation status. Analysis of our previously reported gene expression
proﬁles based upon known PR-A- and PR-B-speciﬁc target genes did not partition samples by
BRCA mutation status, indicating that overall FTE PR response is not altered in BRCA mutation
carriers. HGSC samples grouped separately from other samples, consistent with the observed
loss of PR expression. These ﬁndings indicate no overall difference in PR signalling in FTE as a
function of BRCA mutation status. Thus, the molecular similarity of BRCA1/2-mutated luteal
phase FTE and HGSC likely results from an altered response to luteal phase factors other
than progesterone.
Endocrine-Related Cancer (2011) 18 221–234
Introduction
Epithelial ovarian cancers, which constitute the 5th
leading cause of cancer-related death in North
American women, are thought to arise through two
basic pathways. While most histological subtypes
likely arise from the ovarian surface epithelium
(OSE), accumulating evidence provides strong support
that high-grade serous adnexal cancer, commonly
attributed to an ovarian origin, arises from the distal
fallopian tube epithelium (FTE; Colgan et al. 2001,
Piek et al. 2001, Finch et al. 2006, Medeiros et al.
2006, Crum et al. 2007, Kindelberger et al. 2007,
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previously demonstrated that non-malignant FTE
collected during the luteal phase from breast cancer
susceptibility gene 1/2 (BRCA1/2) mutation carriers
exhibits gene expression proﬁles more closely resem-
bling that of ovarian and fallopian tube high-grade
serous carcinoma (HGSC) than FTE from control
patients (Tone et al. 2008). This ﬁnding suggests that
the FTE of BRCA mutation carriers (FTEb) responds
differently to the luteal phase milieu, which may
contribute to its predisposition to malignant transfor-
mation. Since elevated progesterone secretion is a
hallmark of the luteal phase, the altered gene
expression in these samples may reﬂect a differential
response to progesterone.
Progesterone classically signals by binding to
intracellular progesterone receptors (PR), leading to
receptor dimerisation and binding to speciﬁc hormone
response elements located in the promoter region of
target genes to regulate transcription through
interaction with co-regulatory proteins (Mulac-
Jericevic & Conneely 2004, Shao et al. 2006, Gellersen
et al. 2009). Progesterone can also lead to rapid
activationofanumberofgenesthroughprotein–protein
interactions involving cytoplasmic PR with com-
ponents of the Src/mitogen activated protein kinase,
phosphoinositide 3-kinase/Akt and janus kinase/signal
transducer and activator of transcription signalling
pathways (Leonhardt et al. 2003, Boonyaratanakornkit
et al. 2008, Gellersen et al. 2009). The canonical PR is
expressed as two isoforms, PR-A and PR-B, which are
encoded by a single gene but arise through alternative
useoftwopromoters(Boonyaratanakornkitetal.2008).
PR-A and PR-B are co-expressed at roughly equivalent
levels in most target tissues (Shao et al. 2006). PR-A is
truncated at the amino-terminal domain and has been
shown to exhibit differential functional properties
compared with the full-length PR-B isoform, including
regulation of distinct genes (Jacobsen et al. 2005) and
differential effects on target tissues in knockout mice
(Mulac-Jericevic & Conneely 2004, Shao et al. 2006).
Interestingly, PR-A has been shown to act as a
transdominant inhibitor of PR-B (Vegeto et al. 1993,
Mote et al. 2002), and the relative expression of these
two isoforms has been shown to vary in reproductive
tissues as a result of development and hormonal status
and carcinogenesis (Mulac-Jericevic & Conneely
2004). Phosphorylation of PR in the absence of ligand,
through the activation of cytokine or growth factor
signalling pathways such as epidermal growth factor,
can activate PR-dependent gene expression. In breast
epithelialcells,ligand-independentsignallingisprimarily
through the PR-A isoform (Jacobsen et al. 2005).
The genes regulated by ligand-independent signalling
are largely distinct from those regulated by ligand-
dependent PR activation (Jacobsen et al. 2005). Differ-
ential expression of PR isoforms in FTEb could thus
underlie the altered gene expression proﬁles, particularly
during the luteal phase when circulating progesterone
levels are elevated.
The purpose of this study was to determine whether
PR isoform expression is altered in FTEb relative to
FTE from normal control patients (FTEn), particularly
during the luteal phase. Real-time quantitative
RT-PCR (RT-qPCR) and immunohistochemistry
using isoform-speciﬁc antibodies were performed on
patients’ samples of FTE and HGSC. To our knowl-
edge, this is the ﬁrst comparative study of PR
expression in non-malignant FTE in the follicular and
luteal phases of the ovarian cycle in BRCA1/2 mutation
carriers and control patients.
Materials and methods
Study samples
Gene expression data derived from laser capture
microdissected (LCM) snap-frozen FTE and HGSC
specimens as part of our original proﬁling study (Tone
et al. 2008) were used to evaluate expression levels of
PR and PR-responsive genes. Speciﬁc clinical charac-
teristics associated with these samples were previously
presented (Tone et al. 2008). Brieﬂy, these samples
included histologically normal fallopian tubes from 12
conﬁrmed BRCA1/2 mutation carriers and 12 control
patientsundergoingsalpingo-oophorectomyforreasons
otherthanfamilyhistoryoradnexalmalignancy,and13
HGSC diagnosed as being of tubal or ovarian origin. Of
the 12 BRCA patients, ten had conﬁrmed mutations in
BRCA1 and two had conﬁrmed mutations in BRCA2.
Non-malignant samples were stratiﬁed according to the
phaseofthemenstrualcycle,withsixsamplescollected
during the luteal phase and six collected during the
follicular phase in each group. RNA extracted from the
same representative LCM samples used in our original
study (histologically normal FTE from six BRCA1
mutation carriers and controls from both the luteal and
follicular phases and six HGSC samples) was used to
compare PR expression levels by RT-qPCR.
We constructed two tissue microarrays using
formalin-ﬁxed parafﬁn-embedded samples from the
University Health Network Ovarian Tissue Bank, as
described in our previous publication (Tone et al.
2008). The fallopian tube array included one 1.5 mm
2
core from 11 luteal and 16 follicular phase non-
malignant specimens from conﬁrmed BRCA1/2
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specimens from normal control patients. This array
included the FTEn and FTEb cases that were used for
the original gene expression analysis, as well as
additional samples from the same groups. The second
array included two distinct 0.6 mm
2 cores from
51 cases of HGSC naive to chemotherapy, all but
two of which were independent from those subjected to
gene expression proﬁling. Clinical features of all
carcinoma specimens included in this second tissue
array are shown in Supplementary Table 1, see section
on supplementary data given at the end of this article.
The use of all tissues in this study was approved by the
University Health Network Research Ethics Board, and
all patients provided informed consent.
RT-qPCR for PR mRNA
Real time RT-qPCR was performed as described
previously (Tone et al. 2008) with the following
modiﬁcations. Primer sequences used included PR:
forward 50-GAACAGCGGATGAA-AGAATCATC-30
reverse50-AGGAACTCTTCTTGGCTAACTTGAAG-30;
ACTB: forward 50-GCATTGTTACAGGAAGTC-
CCTTG-30 and reverse 50-CTATCACCTCCCC-
TGTGTG-GA-30. The PR primer pair used recognises
a speciﬁc sequence within the 1500 bp region immedi-
ately upstream of the poly(A) tail and therefore
ampliﬁes both PR-A- and PR-B-speciﬁc transcripts.
Allexperimentsincludedtriplicatewellsofeachsample
forbothtargetandreferencegenes.ThecomparativeCT
method for relative quantitation was performed and
normalised to ACTB expression. A one-way ANOVA
followed by the Newman–Keuls multiple comparison
testwasusedtocomparegroups.Statisticalsigniﬁcance
was determined as P!0.05.
PR isoform-speciﬁc immunohistochemistry
Immunohistochemistry was performed using standard
procedures as described previously (Tone et al. 2008)
with the following modiﬁcations. PR-A protein was
detected using mouse monoclonal anti-PR antibody
(PGR-312 (16), Novocastra Laboratories, Newcastle,
UK; Mote et al. 2001) at a dilution of 1 in 200. PR-B
was detected using anti-PR (B-form) antibody (PGR-B
(SAN27), Novocastra Laboratories) at a dilution of 1 in
200. The ScanScope CS slide scanner (Aperio
Technologies, Inc., Vista, CA, USA) was used to
capture digitised images at 40! magniﬁcation. The
images were then analysed core by core using the
Positive Pixel Count Algorithm included with Image-
Scope software (Aperio Technologies, Inc., version
10.0). This algorithm counts the number of pixels
within three user-deﬁned intensity ranges (weak,
positive and strong). Pixels that are stained but do not
meet the positive colour speciﬁcation are counted as
negative-stained pixels; this is used to determine the
overallpercentageofpositive-stainedpixels.Apseudo-
colour mark-up image is generated as an algorithm
result to conﬁrm the accurate measurement of pixels
within each intensity range (examples shown in
Supplementary Figure 1, see section on supplementary
data given at the end of this article). To control for
potential variability during immunohistochemistry,
duplicate 5 mm sections of the fallopian tube array
were included on each slide. Since the HGSC array
consisted of duplicate distinct cores, the two values for
eachsamplewereaveraged.Statisticalanalysisofmean
percentage of strong staining by sample group was
conducted using ANOVA followed by the Newman–
Keuls multiple comparison test. The distribution of
cases into quartiles was analysed using Pearson’s c
2
test. Comparisons were considered statistically signi-
ﬁcant if P!0.05.
Gene expression analysis
Unsupervised hierarchical clustering was performed on
our original gene expression data based upon corre-
sponding probe sets of potential PR isoform-speciﬁc
genes identiﬁed by Jacobsen et al. (2005). CEL ﬁles
(Gene Expression Omnibus Series accession
#GSE10971) were imported into GeneSpringGX
(version 10.0, Agilent, Santa Clara, CA, USA).
Normalisation was performed, ﬁrst using the robust
multi-array average (RMA) algorithm and then by the
median measurement for each probe set across all
samples. A two-way hierarchical cluster analysis with
average linkage using a Pearson centered similarity
distance metric was then performed.
Classiﬁcation accuracy of subsets of PR isoform-
speciﬁc genes was assessed using the supervised,
shrunken centroid class prediction method (prediction
analysis of microarrays (PAM); Tibshirani et al. 2002)
found in the pamr (v1.44) package of R (v2.10.0,
R Foundation for Statistical Computing, Vienna,
Austria). Each gene set was tested against a predeﬁned
categorical binary variable relevant to a subset of
patient expression data from Tone et al. (2008).
Expression data for each set of patients under
consideration were normalised in GeneSpringGX
independently using the RMA algorithm as well as to
the median expression value of each gene across all
samples. All prediction analyses were performed with
exported log-transformed values in R. In order to use
all the probes under consideration in this prediction
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was used. Model building and prediction was done
using a leave-one-out cross-validation, with the
number of cross validation folds equal to the smallest
number of samples in one of the classes under
consideration.
Results
Decreased expression of PR mRNA in luteal
phase FTE and HGSC specimens
Analysis of previously obtained gene expression
proﬁles of microdissected non-malignant FTE and
HGSC specimens (Tone et al.2 0 0 8 )r e v e a l e da
decreased expression of PR mRNA in FTE samples
obtained during the luteal phase relative to follicular
phase in both BRCA mutation carriers (P!0.001) and
normal controls (P!0.01; Fig. 1A). No differences in
PR mRNA expression were observed in samples
obtained from mutation carriers versus normal controls
during either phase of the ovarian cycle. A subset of
four BRCA1-mutated luteal specimens, which we have
previously highlighted because they grouped closely
with HGSC based on global gene expression (denoted
as FTEb(S); Tone et al. 2008), showed similar
expression of PR compared with other samples
obtained during the luteal phase. Finally, HGSC
specimens exhibited decreased expression of PR,
similar to that observed in the luteal phase FTE.
To conﬁrm these ﬁndings, RT-qPCR was performed
usingRNA from the same representative LCM samples
from each group used for RT-qPCR in our previous
study. Similar to the Affymetrix proﬁling data,
RT-qPCR revealed a decreased expression of PR
mRNA in the luteal versus follicular samples in both
mutation carriers (P!0.05) and controls (P!0.05). In
addition,nodifferencesinPRexpressionwereobserved
between samples obtained from BRCA1/2 mutation
carriers versus normal controls overall or within the
same phase of the cycle (Fig. 1B). Importantly, PR
mRNAwasbarelydetectableinHGSCspecimens,with
expressionlevelsO100-fold lowerthanthoseobserved
in FTEn follicular samples (P!0.01).
Decreased PR-A and PR-B immunostaining in
luteal phase FTE and HGSC specimens
In light of previous studies showing selective loss of
either PR-A or PR-B in ovarian (Akahira et al. 2000,
2002) and breast (Graham et al. 1995, Ariga et al.
2001, Mote et al. 2002, Jacobsen et al. 2005) cancers,
immunohistochemistry was performed on tissue
microarrays using PR-A- or PR-B-speciﬁc antibodies.
Immunostaining for PR-A protein was predominately
nuclear, with differences in staining observed due to
stage of the ovarian cycle and not BRCA mutation
status, consistent with our total PR mRNA results.
A decreased percentage of FTE cells showing strong
PR-A immunopositivity was observed in previously
proﬁled luteal phase FTE relative to follicular phase
samples in both normal controls and BRCA1/2
mutation carriers (P!0.001 for both). No differences
in percentage of strong PR-A staining were observed in
FTEn versus FTEb samples obtained within either the
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Figure 1 Decreased expression of PR mRNA in luteal phase
FTE and HGSC specimens. Panel A shows the expression
of PR in previously obtained gene expression proﬁles of
non-malignant FTE and HGSC, expressed as values obtained
following normalisation by the robust multi-array average
(RMA)algorithm.TheexpressionofPR mRNA(relativetoactin)
in representative samples as determined by RT-qPCR is shown
in panel B. Circles in each panel indicate the individual sample
values, whereas horizontal lines represent average mRNA
expression for each group of samples (FTEn foll, follicular
phase samples from normal controls; FTEn lut, luteal phase
samples from normal controls; FTEb foll, follicular phase
samples from BRCA1/2 mutation carriers; FTEb lut, luteal
phase samples from BRCA1/2 mutation carriers). FTEb(S)
samples are indicated by open circles. Statistically signiﬁcant
differences in average mRNA expression were determined by
one-way ANOVA followed by the Newman–Keuls multiple
comparison test. Sample groups with different letters are
statistically different from one another (P!0.05).
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www.endocrinology-journals.org 224luteal or the follicular phase (Fig. 2A). Of particular
note, expression of PR-A was similar in FTEb(S) and
the remaining FTEb luteal phase cases not previously
found to group with HGSC. These same differential
expression patterns were also observed when PR-A
immunostaining was evaluated in additional FTE
cases not subjected to gene expression proﬁling in
our previous study. In addition, PR-A protein was
barely detectable in an independent set of 51 HGSC
specimens (Fig. 2B).
The percentages of strong PR-A staining for all FTE
cases were ranked by quartiles and compared between
sample groups. A signiﬁcant difference in distribution
was observed between the luteal phase and follicular
phase samples independent of BRCA status, with a
greater proportion of luteal phase samples partitioning
in the lower quartiles (Fig. 2C, P!0.001). While a
slightly higher proportion of FTEb luteal versus FTEn
luteal cases were within the lowest quartile, this
distribution pattern was not statistically signiﬁcant
(PZ0.372). Representative PR-A staining in follicular,
luteal and HGSC specimens is shown in Fig. 2D–F
respectively.
Similar results were obtained for PR-B immunohis-
tochemistry. PR-B staining was decreased in non-
malignant FTE during the luteal phase compared with
that during the follicular phase in both normal controls
and BRCA mutation carriers (P!0.001 for both), in
samples obtained from both previously proﬁled
(Fig. 3A) and additional cases (Fig. 3B). No differences
in PR-B staining were observed in FTEn versus FTEb
overall or within the same stage of the ovarian cycle,
and PR-B was barely detectable in HGSC samples.
A signiﬁcant difference in quartile distribution of
percentages of strong PR-B staining was observed
between the luteal and follicular phase samples
independent of BRCA status, with a greater proportion
of luteal phase samples partitioning in the lower
quartiles (Fig. 3C, P!0.001). The distribution of cases
was strikingly similar in normal controls compared
with mutation carriers. Representative staining for
follicular, luteal and HGSC specimens is shown in
Fig. 3D–F. Altogether, these data indicate that both
PR-A and PR-B protein levels vary according to the
stage of the ovarian cycle, and not BRCA mutation
status. Similar results were obtained when images were
analysed using an alternative image analysis program
(Visiomorph software, Visiopharm, Hoersholm,
Denmark; data not shown).
The analyses presented in this study largely reﬂect
nuclear PR levels. Cytoplasmic staining was observed
for PR-A and PR-B; however, the staining was less
intense and present in fewer cells than nuclear staining.
A difference due to the cycle stage was observed in
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Figure 2 Decreased PR-A immunostaining in luteal phase FTE and HGSC specimens. Immunohistochemistry was performed on
tissue microarrays using a PR-A-speciﬁc antibody, and the number of weak-positive, medium-positive and strong-positive pixels in
eachsample was quantiﬁedusing the PositivePixel CountAlgorithm.The percentageofstrong PR-Aimmunostainingin tissuecores
obtained from previously proﬁled FTE samples (A) and additional FTE and HGSC specimens (B) is shown. Circles in A and B
denote the percentage of strong PR-A immunostaining in individual samples, with FTEb(S) samples indicated by open circles in A.
Horizontal lines represent average percentage of strong PR-A staining for each group of samples, and groups with different letters
are statistically different from one another (as determined by one-way ANOVA followed by the Newman–Keuls multiple comparison
test; P!0.05). Panel C shows the distribution of samples following ranking of PR-A immunostaining data by quartiles (0, !1st
quartile; 1, 1–2nd quartiles; 2, 2–3rd quartiles; 3, O3rd quartile). The distribution of cases into quartiles was analysed using
Pearson’s c
2 test, with comparisons considered statistically signiﬁcant if P!0.05. Representative PR-A immunostaining in follicular
FTE (D), luteal FTE (E) and HGSC (F) samples is shown (magniﬁcation 20!).
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in the luteal phase samples regardless of BRCA
mutation status. In contrast, cytoplasmic PR-B staining
did not differ with either cycle stage or mutation status
(Supplementary Figure 2, see section on supple-
mentary data given at the end of this article).
Because PR-A has been found to affect signalling by
PR-B,the relative levels of these two isoforms couldbe
important to the resultant progesterone signalling. The
ratio of the total percentage of cells positive for PR-A
versus PR-B (PR-A:PR-B ratio) in the same selected
area was calculated for each case and compared
between FTE groups. No statistically signiﬁcant
differences in average PR-A:PR-B ratio were observed
in the luteal phase compared with follicular phase
samples, or normal controls versus BRCA mutation
carriers (Fig. 4A). Interestingly, individual PR-A:PR-B
values were tightly grouped in the follicular phase
samples, whereas a greater range of ratios was
observed in the luteal phase samples. This could
potentially reﬂect different times of the luteal phase
when samples were collected, as progesterone
secretion is variable during this phase, reaching peak
levels at 5 days post-ovulation. In contrast, very little
progesterone is secreted throughout the duration of the
follicular phase. Ranking of PR-A:PR-B ratio data by
quartiles revealed an overall difference in distribution
among the four FTE groups (PZ0.006). A greater
proportion of luteal phase compared with follicular
phase samples partitioned in the lowest quartile
(PZ0.003; Fig. 4B). In contrast, there was no
statistically signiﬁcant difference in the distribution
pattern due to BRCA mutation status overall
(PZ0.129) or in BRCA mutation carriers versus
normal controls during the luteal phase (PZ0.09).
These data suggest a subtle shift in the PR-A:PR-B
staining ratio during the luteal phase, potentially
reﬂective of a slightly lower level of PR-A relative to
PR-B during this phase.
Gene expression analysis of proﬁled FTE based
on proposed PR-A and PR-B target genes
To determine whether the expression of PR-dependent
genes separates FTE samples into meaningful sub-
groups, unsupervised clustering of all individual
samples was performed using genes previously shown
to be altered downstream of PR activation by Jacobsen
et al.(2005).Genes with altered expression speciﬁcally
due to PR-A or PR-B activation, both dependent and
independent of ligand, were identiﬁed in oestrogen
receptor (ER)-positive, PR-negative T47D breast
cancer cell lines engineered to express PR-A or PR-B
under the control of an inducible promoter (Jacobsen
et al. 2005). Speciﬁcally, 37 distinct genes were
found to be altered in PR-AC (relative to PR null)
AC B
DE F
0
1
2
3
0
P
e
r
c
e
n
t
a
g
e
 
o
f
 
c
a
s
e
s
 
s
t
r
o
n
g
P
R
-
B
 
s
t
a
i
n
i
n
g
80
60
40
20
FTEn foll
(n=6)
FTEn lut
(n=6)
FTEb foll
(n=6)
FTEb lut
(n=6)
0
10
20
30
40
P
e
r
c
e
n
t
a
g
e
 
o
f
 
s
t
r
o
n
g
 
P
R
-
B
 
s
t
a
i
n
i
n
g
a
b
a
b
P
e
r
c
e
n
t
a
g
e
 
o
f
 
s
t
r
o
n
g
 
P
R
-
B
 
s
t
a
i
n
i
n
g
a
b
a
b
c
Profiled FTE samples Additional FTE + HGSC samples
0
10
20
30
40
FTEn follicular
(n=12)
FTEn luteal
(n=11)
FTEb follicular
(n=16)
FTEb luteal
(n=11)
FTEn lut
(n =5)
FTEn foll
(n=6)
FTEb foll
(n=10)
FTEb lut
(n=5)
HGSC
(n=51)
Figure 3 Decreased PR-B immunostaining in luteal phase FTE and HGSC specimens. Immunohistochemistry was performed using
a PR-B-speciﬁc antibody and quantiﬁed using the Positive Pixel Count Algorithm. The percentage of cells with strong PR-B
immunostaining in previously proﬁled FTE cases (A) and independent FTE and HGSC (B) is shown. Circles in A and B denote the
percentage of cells with strong PR-B immunopositivity in individual samples, with FTEb(S) samples indicated by open circles.
Horizontal lines represent average percentage of strong PR-B staining by group, and groups with different letters are statistically
different from one another (as determined by one-way ANOVA followed by the Newman–Keuls multiple comparison test; P!0.05).
Panel C shows the distribution of samples following ranking of PR-B immunostaining data by quartiles (0, !1st quartile; 1, 1–2nd
quartiles; 2, 2–3rd quartiles; 3, O3rd quartile). The distribution of cases into quartiles was analysed using Pearson’s c
2 test, with
comparisons considered statistically signiﬁcant if P!0.05. Representative PR-B immunostaining in follicular FTE (D), luteal FTE (E)
and HGSC (F) samples is shown (magniﬁcation 20!).
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speciﬁcally altered in PR-B-expressing cells at the
same time point (see Supplementary Tables 2 and 3,
see section on supplementary data given at the end of
this article for PR-A- and PR-B-dependent genes
extracted from Jacobsen et al. that are included in the
current analysis). Probe sets representing each of these
genes were identiﬁed in the Affymetrix 2.0 Plus arrays
(a total of 94 for PR-A-dependent genes and 118 for
PR-B-dependent genes), and each list of probe sets was
used separately to cluster our original proﬁling data.
In this study, unsupervised hierarchical clustering of
FTE and HGSC based on probe sets corresponding to
all (both ligand-dependent and -independent) PR-A-
dependent genes resulted in two main cluster groups
(ICII), each of which further divided into two
subgroups (aCb; Fig. 5). A clear separation of non-
malignant samples based on BRCA1/2 mutation status
or cycle stage was not observed based on the
expression of these genes. While group Ia consisted
of mostly follicular samples and one luteal sample with
the highest PR-A staining, group Ib consisted of a mix
of luteal and follicular phase samples from both
mutation carriers and normal controls. Notably,
FTEb(S) samples all partitioned together (within
group IIa) separate from the remaining FTEb luteal
samples (group I). However, the presence of FTEn
luteal samples in both of these cluster groups indicates
that BRCA mutation status does not affect the
expression of PR-A-responsive genes. Importantly,
12 of the 13 HGSC specimens partitioned separately
from non-malignant FTE; since the HGSCs all express
low levels of PR, this pattern is consistent with the PR
dependence of this cassette of genes.
Similar results were obtained when unsupervised
cluster analysis was performed using probe sets
corresponding to genes speciﬁcally altered down-
stream of PR-B activation (Fig. 6). There were two
main cluster groups, with no clear separation of non-
malignant samples by BRCA mutation status or cycle
stage. Group Ia consisted of a mix of FTEn and FTEb
samples from both the follicular and luteal phases.
FTEb(S) samples partitioned together within group Ib
separate from the majority of HGSC in group II.
To extend our analysis of PR-dependent gene
expression in FTE and HGSC, we tested the ability
of these probe sets to predict a given sample category
using a shrunken centroid classiﬁcation methodology
(Tibshirani et al. 2002; results shown in Table 1).
A threshold of 0 for the shrinkage factor was used in
order to include all probe sets in the prediction, and all
results are based on a leave-one-out cross-validation
analysis. Similar to the cluster analysis presented
above, PR-A- and PR-B dependent genes were
evaluated separately, and PR-A target genes were
further subdivided into those found to be altered
dependent (‘PR-A ligand-dependent’) and independent
of the presence of ligand (‘PR-A ligand-independent’)
in T47D cells. We chose to include the latter set of
genes in our analysis (despite being altered in the
absence of progesterone), since the ligand dependency
of a particular gene may be inﬂuenced by cell or tissue
type. As exposure to progesterone leads to down-
regulation of both PR isoforms (Lange et al. 2000),
gene expression could also be altered by decreased
levels of PR-A irrespective of the absence or presence
of ligand. Furthermore, if ligand-independent genes
were found to be predictive of BRCA mutation status,
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Figure 4 Overall ratio of PR-A to PR-B immunostaining in non-
malignant FTE specimens. The ratio of the total percentage of
cells positive for PR-A versus PR-B (PR-A:PR-B ratio) in the
same selected area was calculated for each FTE case (taking
into account weak-, medium- and strong-positive pixels)* and
compared between sample groups (shown in panel A). Circles
denote the calculated PR-A:PR-B ratio for individual samples,
withFTEb(S)samplesindicatedbyopencircles.Horizontallines
represent average PR-A:PR-B by group. Panel B shows the
distribution of samples following ranking of all PR-A:PR-B data
by quartiles (0, !1st quartile; 1, 1–2nd quartiles; 2, 2–3rd
quartiles; 3, O3rd quartile). The distribution of cases into
quartiles was analysed using Pearson’s c
2 test, with compari-
sons considered statistically signiﬁcant if P!0.05. The average
overalllevelsofPR-AandPR-BstainingbyFTEgroup(GS.E.M.)
were as follows: FTEn follicular, PR-A 86.1G1.8% and PR-B
89.1G1.7%; FTEn luteal, PR-A 63.1G5.9% and PR-B 70.8
G4.1%; FTEb follicular, PR-A 83.7G1.8% and PR-B 86.4
G1.6%; FTEb luteal, PR-A 60.8G5.2% and PR-B 67.6G3.9%.
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PR and cytokine signalling pathways that may be
locally elevated following ovulation (Denner et al.
1990, Pierson-Mullany & Lange 2004). In contrast to
PR-A, only two PR-B-speciﬁc genes were reported to
be altered independent of progesterone in T47D cells
(Jacobsen et al. 2005), so a separate analysis was not
performed for PR-B. Consistent with unsupervised
clustering, PR-dependent genes were predictive of
whether a particular sample was non-malignant FTE or
HGSC (as indicated by a high sample prediction
accuracy for each list using dataset A, total nZ37
samples). In contrast, none of the PR-dependent
subsets (particularly probe sets corresponding to
PR-A ligand-independent genes) were successful at
predicting whether a particular non-malignant sample
was obtained from a BRCA1/2 mutation carrier or
control patient (as indicated by a low sample prediction
accuracy for dataset B, total nZ24 samples), indicat-
ing that the overall PR response is not altered due to
BRCA mutation status. As expected, all lists were
predictive of the stage of the ovarian cycle of a given
FTE sample (dataset C, total nZ24 samples),
providing further support of the PR dependence of
the genes identiﬁed by Jacobsen et al. (2005). Finally,
certain subsets of PR-dependent genes (such as those
activated by PR-A overall and PR-B) were relatively
successful at predicting whether a particular luteal
phase sample belonged to the FTEb(S) subgroup
(dataset D, total nZ12 samples).
Discussion
The data presented in this study demonstrate that PR
expression in the FTE is altered as a function of the
ovarian cycle. PR mRNA and protein were decreased
during the luteal phase, and this represented a
decreased expression of both PR-A and PR-B isoforms
in both previously proﬁled and independent FTE
samples. A major question addressed in this study
was whether PR levels are affected by BRCA mutation
status, and whether this could be PR isoform speciﬁc.
Ia IIa Ib IIb
Cycle
Type
Figure 5 Clustering of proﬁled non-malignant FTE and HGSC samples using PR-A-dependent probe sets. Unsupervised
hierarchical clustering was performed on our original proﬁling data, using a cassette of probe sets corresponding to genes previously
found to be speciﬁcally altered following PR-A activation. Two main cluster groups emerged (shown at the bottom). The cluster tree
is shown at the top, with each line representing one sample. The type of sample is indicated at the bottom of the heatmap (blue,
FTEn; red, FTEb; green, tubal HGSC; black, ovarian HGSC), with the stage of the ovarian cycle for each FTE sample indicated
below (purple, follicular; yellow, luteal). *Denotes each FTEb(S) sample.
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overtly impact PR-A and PR-B expression in the FTE.
Unsupervised clustering and sample prediction
analyses using genes reported as PR-A- and PR-B-
speciﬁc targets further showed that BRCA-mutated
samples did not exhibit an altered PR response.
The ﬁnding that PR mRNA is lowest during the
luteal phase (in both carriers and controls) is consistent
with previous studies of normal human FTE through-
out the ovarian cycle, which have shown little or no PR
expression during this phase as determined by semi-
quantitative RT-PCR (Briton-Jones et al. 2005).
Similar results have also been obtained for total PR
protein, and the sharp decline in PR was found to
coincide with the luteal elevation of serum pro-
gesterone concentration in these studies (Verhage
et al. 1980, Pino et al. 1984, Helm et al. 1987). This
is consistent with studies demonstrating the poly-
ubiquitination and subsequent degradation of PR
protein upon exposure to progesterone (Lange et al.
2000). Thus, the decline in PR expression in the luteal
phase samples observed in this study likely represents
downregulation of PR.
Our results further demonstrate a strong down-
regulation of PR expression in HGSC. This is
consistent with several studies that have reported
decreased expression of PR in ovarian and fallopian
tube cancers. Lau et al. (1999) have demonstrated a
marked reduction in PR mRNA in ovarian cancer cell
lines compared with primary cultures of normal OSE
using semi-quantitative RT-PCR, and others have
found low PR protein expression in both BRCA1-
associated and sporadic serous ovarian cancers by
immunohistochemistry (Aghmesheh et al. 2005).
However, recent studies have strongly suggested that
the FTE is the source of HGSC (Colgan et al. 2001,
Piek et al. 2001, Finch et al. 2006, Medeiros et al.
2006, Crum et al. 2007, Kindelberger et al. 2007,
Folkins et al. 2008, Shaw et al. 2009), thus the OSE
may not be the appropriate comparator. A single
previous study has reported slightly decreased PR
protein expression in fallopian tube carcinomas
relative to areas of benign FTE in patients with or
without a BRCA mutation (Cass et al. 2005). Our study
extends these observations to both tubal and ovarian
HGSC samples and to FTE samples obtained from
Cycle
Type
Ia II Ib
Figure 6 Clustering of proﬁled non-malignant FTE and HGSC samples using PR-B-dependent probe sets. Unsupervised
hierarchical clustering of FTE and HGSC using probe sets corresponding to genes speciﬁcally altered downstream of PR-B
activation revealed two main sample groupings (indicated at bottom). Sample type is indicated at the bottom (blue, FTEn; red, FTEb;
green, tubal HGSC; black, ovarian HGSC), with the stage of the ovarian cycle for each FTE sample indicated below (purple,
follicular; yellow, luteal). *Denotes each FTEb(S) sample.
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demonstrate a strong downregulation of PR expression
in HGSC samples, such that PR expression is nearly
absent in malignant cells. Interestingly, previous
studies have demonstrated loss of heterozygosity
(LOH) at the PR locus (11q22) in up to 50% of
analysed ovarian carcinomas of varying histotypes
(Gabra et al. 1995, Launonen et al. 1998), providing a
potential explanation for PR loss in HGSC specimens.
In one such study, 6/15 (40%) of informative serous
carcinoma specimens exhibited LOH; furthermore,
LOH at 11q22 was signiﬁcantly associated with low
tumour PR content in the full cohort of 38 ovarian
carcinomas studied (Gabra et al. 1995). Whether LOH
occurs in HGSC precursor lesions in the FTE remains
to be determined.
Expression of PR has be e nr e p o r t e dt ob ea
favourable prognostic indicator in ovarian cancer
(Lee et al. 2005), but this ﬁnding may be misleading
due to the inclusion of multiple histotypes in the
analysis. Close examination of the reported data
indicates that 64% of endometrioid carcinomas were
considered positive for PR (O10% of cells stained),
compared with only 25% of serous carcinomas of
unspeciﬁed grade. Patients with endometrioid carci-
nomas typically present at an earlier stage and have a
greatly enhanced survival (Gien et al. 2008), which
could underlie the apparent impact of PR expression on
prognosis in this study. The tissue microarray used in
this study to assess PR expression in HGSC also
contained other major histotypes of epithelial ovarian
cancer (see Supplementary Table 1, see section on
supplementary data given at the end of this article for
the clinical characteristics and immunostaining results
of individual carcinoma cases). Consistent with the
data presented in the previous study, 11/14 (79%) and
12/12 (100%) of evaluable endometrioid cases,
compared with 10/51 (20%) and 13/51 (25%) of
HGSC cases, showed O10% positivity for PR-A and
PR-B respectively (Supplementary Figure 3,s e e
section on supplementary data given at the end of
this article). Also consistent was our ﬁnding that none
of the clear cell carcinomas and only one of six
mucinous carcinomas examined showed positive PR-A
or PR-B staining, suggesting a potential role for PR
loss in these histotypes.
The relative levels of PR-A and PR-B inﬂuence the
response of target cells to progesterone. For instance,
breast cancer cells with predominant expression of
PR-A have shown an exaggerated proliferative
response to luteal phase levels of progesterone
compared with cells with predominant expression of
PR-B (Leo & Lin 2008). While PR-A and PR-B are
expressed at roughly equivalent levels in normal
human breast epithelium throughout the cycle, several
studies have found a predominance of PR-A in a high
proportion of invasive breast tumours (Graham et al.
1995, Ariga et al. 2001, Mote et al. 2002) and in ductal
carcinomas in situ (Mote et al. 2002). A speciﬁc lack of
expression of the PR-B isoform has also been observed
in normal breast epithelium obtained from BRCA
mutation carriers compared with control patients,
resulting in predominant expression of PR-A in 40%
of cases (Mote et al. 2004).
Table 1 Accuracy for predicting sample categories based on sets of PR-dependent genes using the shrunken centroid classiﬁcation
methodology of Tibshirani et al. with a threshold of 0 (all probes used for prediction)
Dataset Prediction
a
PR-A
prediction
b
accuracy
PR-A
LD prediction
b
accuracy
PR-A
LI prediction
b
accuracy
PR-B prediction
b
accuracy
cA. Non-malignant FTE Non-malignant 24/24 (100%) 24/24 (100%) 24/24 (100%) 24/24 (100%)
versus HGSC Cancer 12/13 (92.3%) 11/13 (84.6%) 12/13 (92.3%) 12/13 (92.3%)
dB. FTEn FTEn 6/12 (50%) 8/12 (66.7%) 3/12 (25%) 4/12 (33.3%)
versus FTEb FTEb 7/12 (58.3%) 8/12 (66.7%) 4/12 (33.3%) 5/12 (41.7%)
dC. Luteal Luteal 9/12 (75%) 9/12 (75%) 9/12 (75%) 10/12 (83.3%)
versus follicular Follicular 11/12 (91.7%) 11/12 (91.7%) 10/12 (83.3%) 11/12 (91.7%)
eD. FTEb(S) FTEb(S) 3/4 (75%) 3/4 (75%) 2/4 (50%) 3/4 (75%)
versus other luteal Other luteal 7/8 (87.5%) 6/8 (75%) 7/8 (87.5%) 8/8 (100%)
LD, ligand dependent, LI, ligand independent.
aIndicates the sample type attempting to be predicted based on the expression of a given set of PR-dependent genes.
bIndicates the proportion of samples in a given category that are predicted correctly based on the expression of a given set of
PR-dependent genes. A high prediction accuracy suggests that a given set of PR-dependent genes is successful at differentiating
between the two sample types included in the analysis.
cExpression data from all non-malignant FTE (nZ24) and HGSC (nZ13) samples included in prediction analysis.
dExpression data from all non-malignant FTE (nZ24) samples included in prediction analysis following independent normalisation.
eExpression data from all non-malignant FTE obtained during the luteal phase (nZ12) included in prediction analysis following
independent normalisation.
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both PR-A and PR-B in HGSC relative to its probable
cell type of origin. Because expression of both
isoforms in HGSC was barely detectable by immuno-
histochemistry, consistent with our RT-qPCR data,
ratios of PR-A to PR-B were not calculated. Akahira
et al. (2000) have demonstrated a lower expression of
PR-A compared with PR-B for all epithelial ovarian
cancer histotypes using both RT-PCR and immuno-
histochemistry; relative isoform levels did not vary
with grade or stage of tumour. In a follow-up study,
this group reported a progressive downregulation of
PR-A, but not of PR-B, from normal OSE through
benign, borderline and malignant serous ovarian
tumours (Akahira et al. 2002). In normal OSE and
serous adenomas, both isoforms were equally
expressed, whereas PR-B predominated in borderline
and malignant tumours. However, the grade of the
serous carcinomas was not indicated, and while low-
grade serous carcinomas are thought to be derived from
borderline tumours (Singer et al. 2002, Shih & Kurman
2004, May et al. 2010), this is not thought to be the
case for HGSC. In light of recent studies outlining the
progression to HGSC from normal FTE (Crum et al.
2007, Lee et al. 2007, Folkins et al.2 0 0 8 ), studies of
relative PR isoform expression in FTE exhibiting focal
accumulation of p53 (p53 signatures), tubal intra-
epithelial carcinomasandtheirproposedintermediaries
should be performed to determine whether differential
isoform expression may play a role at any stage during
HGSC development.
A study comparing steroid receptor expression in
familial and sporadic serous carcinomas reported no
statistical difference in either PR-A or PR-B expression
(Aghmesheh et al. 2005). Initial studies investigating
the effect of BRCA mutation status on PR expression in
non-malignant cells did not distinguish by isoform, but
rather focused on determining total PR protein levels.
In these studies, no differential expression was
observed in non-malignant FTE and OSE from
mutation carriers and controls (Piek et al. 2001,
2003). PR protein was expressed abundantly in both
ciliated and secretory FTE cells, and expression in
morphologically normal and dysplastic areas from
mutation carriers was similar (Piek et al. 2001). This is
consistent with our ﬁndings of no differences in either
PR-A or PR-B expression as a function of BRCA
mutation status. In studies of BRCA-associated OSE,
the only difference observed was an increased
expression of PR protein in inclusion cyst epithelium
compared with OSE, which the authors attributed to an
increased exposure to ovarian stroma-derived hor-
mones including oestrogen (Piek et al.2 0 0 3 ).
Interestingly, PR expression was higher in inclusion
cyst epithelium from mutation carriers compared with
controls, potentially consistent with the repression of
ER transactivation activity by wild-type BRCA1
(Zheng et al. 2001, Fan et al. 2002). BRCA1 has also
been reported to function as a PR transcriptional
repressor (Ma et al. 2006); thus we had expected to see
a separation of FTEb and FTEn cases based on
established PR-responsive genes. However, the
response to progesterone was not affected by mutation
status, as indicated by a lack of separation of FTEn and
FTEb samples by unsupervised clustering based on
PR-A- or PR-B-dependent genes. Furthermore, a low
proportion of FTEn and FTEb samples were placed in
t h ec o r r e c tc a t e g o r yw h e na t t e m p t i n gt op r e d i c t
whether a particular FTE sample was obtained from
a BRCA1/2 mutation carrier or a normal control using
the same subsets of PR-dependent genes. If altered PR
signalling is in fact an important contributor to the
initiation of HGSC, we would expect to observe a clear
separation of FTEn and FTEb samples by unsupervised
clustering and a higher accuracy rate in sample predic-
tion analysis given the greatly enhanced risk of HGSC
in BRCA1/2 mutation carriers. In contrast to FTEn
versus FTEb, PR-dependent genes could successfully
differentiate malignant versus non-malignant samples,
utilising both unsupervised clustering and sample
prediction analysis. This is not unexpected, as HGSC
samples showed a universal loss of PR expression
compared with non-malignant FTE. It is important to
note that the gene expression analysis presented in this
study is based on target genes identiﬁed in breast
cancer cells and does not reﬂect genes affected in a
tissue-speciﬁc manner. A more deﬁnitive analysis
therefore awaits the identiﬁcation of PR target genes
more speciﬁc to FTE cells.
Several studies suggest that HGSC arises from the
secretory rather than the ciliated FTE (Talamo et al.
1982, Crum et al. 2007, Lee et al.2 0 0 7 ). One
possibility, therefore, for the partitioning of luteal
phase samples with HGSC may be an enrichment of
secretory cells in the FTE during the luteal phase.
However, studies indicate that the secretory cell type is
not overrepresented during this phase. The relative
proportions of secretory to ciliated cells in different
segments of the human fallopian tube throughout the
ovarian cycle were previously studied by Crow et al.
(1994). They reported an increase in the proportion of
ciliated cells (hence a decrease in the proportion of
secretory cells) along the length of the tube, with the
highest proportion of ciliated cells observed in the
ﬁmbriae (the location of the overwhelming majority of
HGSC precursor lesions). Importantly, they reported
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secretory versus ciliated cells in the luteal versus
follicular phase. For example, only 4% more secretory
cells were observed in the ﬁmbriated end in the luteal
phase compared with the follicular phase. This slight
difference would have a negligible impact on global
gene expression. We found that luteal samples, in
general, grouped separately from follicular phase
samples by unsupervised clustering, which is consist-
ent with the increased presence of progesterone during
the luteal phase. Our ﬁnding of a high accuracy rate
with PR ligand-independent gene expression in
differentiating the luteal and follicular phase samples
could reﬂect the changes in PR expression as well as
indicate that signalling pathways resulting in PR
phosphorylation differ with the ovarian cycle.
Our previous work provides evidence suggesting
that a differential response by FTE from BRCA
mutation carriers to the luteal phase milieu contributes
to an increased propensity for malignant transfor-
mation. FTE from BRCA mutation carriers collected
during the luteal phase molecularly resembled HGSC,
rather than FTE collected during the follicular phase or
from normal control patients. This was particularly
apparent for four FTEb luteal samples, referred to as
FTEb(S), which grouped with HGSC at the global gene
expression level (Tone et al. 2008). In this study, we
investigated the potential for altered PR expression and
signalling to contribute to this differential gene
expression pattern. Our results indicate that there is
no overt difference in PR expression as a function of
BRCA mutation status. Unsupervised cluster analysis
further indicated that a differential response to
progesterone based on BRCA mutation status also
does not likely underlie the molecular similarity of
FTEb(S) and HGSC samples, as FTEb(S) samples
were found to group separately from the majority of
HGSC according to the expression of PR-dependent
genes. As we learn more about the speciﬁc role of
PR-A and PR-B in the fallopian tube, a reﬁned set of
genes will likely emerge. It therefore remains possible
that a differential clustering pattern could result with a
tissue-speciﬁc gene list. However, based on the
information that is presently available, our data
indicate that differential response to factors associated
with the luteal phase other than progesterone plays an
important role in determining HGSC risk.
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